258 related articles for article (PubMed ID: 26067223)
1. Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort.
Yan X; Fu X; Cai C; Zi X; Yao H; Qiu Y
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1180-6. PubMed ID: 26067223
[TBL] [Abstract][Full Text] [Related]
2. Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore.
Selby LK; Tay RX; Woon WW; Low JK; Bei W; Shelat VG; Pang TC; Junnarkar SP
J Hepatobiliary Pancreat Sci; 2017 Mar; 24(3):143-152. PubMed ID: 28012284
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the Hong Kong Liver Cancer Staging System in Europe.
Kolly P; Reeves H; Sangro B; Knöpfli M; Candinas D; Dufour JF
Liver Int; 2016 Jun; 36(6):911-7. PubMed ID: 26677809
[TBL] [Abstract][Full Text] [Related]
4. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.
Yau T; Tang VY; Yao TJ; Fan ST; Lo CM; Poon RT
Gastroenterology; 2014 Jun; 146(7):1691-700.e3. PubMed ID: 24583061
[TBL] [Abstract][Full Text] [Related]
5. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.
Heinrich S; Sprinzl M; Schmidtmann I; Heil E; Koch S; Czauderna C; Heinrich B; Philippe P Diggs L; Wörns MA; Kloeckner R; Galle PR; Marquardt JU; Weinmann A
United European Gastroenterol J; 2020 May; 8(4):444-452. PubMed ID: 32213028
[TBL] [Abstract][Full Text] [Related]
6. Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization.
Zhong BY; Ni CF; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Teng GJ
Cardiovasc Intervent Radiol; 2018 Dec; 41(12):1867-1876. PubMed ID: 30073478
[TBL] [Abstract][Full Text] [Related]
7. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
[TBL] [Abstract][Full Text] [Related]
8. Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.
Li JW; Goh BG; Chang PE; Tan CK
World J Gastroenterol; 2017 Jun; 23(22):4054-4063. PubMed ID: 28652658
[TBL] [Abstract][Full Text] [Related]
9. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.
Lee YS; Seo YS; Kim JH; Lee J; Kim HR; Yoo YJ; Kim TS; Kang SH; Suh SJ; Joo MK; Jung YK; Lee BJ; Yim HJ; Yeon JE; Kim JS; Park JJ; Um SH; Bak YT; Byun KS
Gut Liver; 2018 Jan; 12(1):94-101. PubMed ID: 28873509
[TBL] [Abstract][Full Text] [Related]
10. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.
Sohn JH; Duran R; Zhao Y; Fleckenstein F; Chapiro J; Sahu S; Schernthaner RE; Qian T; Lee H; Zhao L; Hamilton J; Frangakis C; Lin M; Salem R; Geschwind JF
Clin Gastroenterol Hepatol; 2017 May; 15(5):746-755.e4. PubMed ID: 27847278
[TBL] [Abstract][Full Text] [Related]
11. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology.
Liu PH; Hsu CY; Lee YH; Su CW; Hsia CY; Huang YH; Chiou YY; Lin HC; Huo TI
Medicine (Baltimore); 2015 Oct; 94(41):e1772. PubMed ID: 26469917
[TBL] [Abstract][Full Text] [Related]
12. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?
Kim KM; Sinn DH; Jung SH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2016 Oct; 36(10):1490-7. PubMed ID: 26936471
[TBL] [Abstract][Full Text] [Related]
13. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients.
Liu PH; Hsu CY; Hsia CY; Lee YH; Huang YH; Su CW; Lee FY; Lin HC; Huo TI
Eur J Cancer; 2016 Aug; 63():25-33. PubMed ID: 27259100
[TBL] [Abstract][Full Text] [Related]
14. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
Longo L; Rodrigues de Freitas LB; Santos D; Grivicich I; Álvares-da-Silva MR
Am J Clin Oncol; 2019 May; 42(5):466-471. PubMed ID: 30913090
[TBL] [Abstract][Full Text] [Related]
15. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.
Wallace MC; Huang Y; Preen DB; Garas G; Adams LA; MacQuillan G; Tibballs J; Ferguson J; Samuelson S; Jeffrey GP
Dig Dis Sci; 2017 Aug; 62(8):2182-2192. PubMed ID: 28547649
[TBL] [Abstract][Full Text] [Related]
16. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
[TBL] [Abstract][Full Text] [Related]
17. Prospective validation of the Barcelona Clinic Liver Cancer staging system.
Cillo U; Vitale A; Grigoletto F; Farinati F; Brolese A; Zanus G; Neri D; Boccagni P; Srsen N; D'Amico F; Ciarleglio FA; Bridda A; D'Amico DF
J Hepatol; 2006 Apr; 44(4):723-31. PubMed ID: 16488051
[TBL] [Abstract][Full Text] [Related]
18. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system.
Hsu CY; Lee YH; Hsia CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Lee FY; Huo TI
Hepatology; 2013 Jan; 57(1):112-9. PubMed ID: 22806819
[TBL] [Abstract][Full Text] [Related]
19. [Evaluations of seven different clinical staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection].
Zhao J; Yan T; Huang Z; Bi X; Zhao H; Zhou J; Li Z; Li Y; Li C; Cai J
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):903-7. PubMed ID: 24854909
[TBL] [Abstract][Full Text] [Related]
20. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey.
Huo TI; Lin HC; Hsia CY; Wu JC; Lee PC; Chi CW; Lee SD
Am J Gastroenterol; 2007 Sep; 102(9):1920-30. PubMed ID: 17573792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
